- Repligen (RGEN) receives its first $1M milestone payment from Pfizer (PFE) related to the companies' licensing agreement for spinal muscular atrophy compounds.
- RGEN received $5M upfront and is eligible to receive as much as $64M more under the terms of the deal, not including royalties from any marketed compounds.
- The spinal muscular atrophy program was out-licensed to PFE in order to allow RGEN to focus on its bioprocessing business while still preserving the economic value of the therapeutics business for shareholders. (PR)
Repligen gets first milestone payment from Pfizer for SMA program
Sep 4 2013, 07:59 ET